TNGXTango Therapeutics, Inc.
Price
+155%1YEnd-of-day closes, not the intraday tick.
A mixed picture: the questions disagree
Quality shaky, nothing alarming, growing in the filings, the market undecided.
TNG456 is a brain-penetrant PRMT5 inhibitor. In May 2025, the first patient was treated with TNG456 in the dose escalation portion of the Phase 1/2 clinical trial to evaluate the safety, pharmacokinetics, pharmacodynamics and antitumor activity of TNG456 as a monotherapy. The trial is currently enrolling patients with MTAP-deleted solid tumors, with a focus on GBM. We anticipate providing a safety and efficacy update from this trial in 2026.
In the company’s own words · 10-K filed Mar 5, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Tango Therapeutics, Inc. (TNGX) reported revenue of $3.7M in Q2 2026 (quarter ended Jun 30, 2026), up 17% from the same quarter a year earlier. That came with net loss of $55M. For the full year FY2025, revenue was $62M (+48% year on year) and net income −$102M. Its largest product in Q2 2024 (quarter ended Jun 30, 2024) was License at $12M, 61% of the disclosed total, well ahead of Collaboration at 39%. The next results filing is expected around Nov 3, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Oct 23, 2026Promising Results from Phase 1/2 Clinical Trial of Vopimetostat in Combination with RAS(ON) Inhibitors On October 23, 2026, the Company disclosed promising results from its ongoing Phase 1/2 trial evaluating vopimetostat in combination with RAS(ON) inhibitors from Revolution Medicines, Inc. in patients with …Regulation FD disclosure · Form 8-K
- Aug 11, 2026As previously disclosed, on November 21, 2025, Tango Therapeutics, Inc. (the “Company”) entered into a Sales Agreement (the “Sales Agreement”) with Leerink Partners LLC (the “Sales Agent”), with respect to an at-the-market offering program pursuant to which the Company may offer and sell, from time to time at its sole …Other event · Form 8-K
- Aug 11, 2026Tango Therapeutics Reports Second Quarter 2026 Financial Results.Earnings release · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Q2 2024 · $19.9MThe company’s own SEC segment disclosure.
- License$12.1M61%
- Collaboration$7.8M39%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.